SALAT JONES: Open Payments
NPI 1396473294 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,764 in 93 payments from 17 companies in 2025. Trend: 2023 $24 · 2024 $712 · 2025 $1,764
Food & beverage: $1,764
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $309 |
| ABBVIE INC. | 21 | $233 |
| Otsuka America Pharmaceutical, Inc. | 12 | $198 |
| Alpha Cognition USA, Inc. | 8 | $193 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $162 |
| Alkermes, Inc. | 6 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $90 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| Lundbeck LLC | 3 | $71 |
| Neos Therapeutics, LP | 3 | $61 |
Products named: INGREZZA, VRAYLAR, REXULTI, Zunveyl, CAPLYTA, ARISTADA, TRINTELLIX, Auvelity.
Industry payments across MO — which companies pay providers there.
